XM, Amerika Birleşik Devletleri'nde ikamet edenlere hizmet sunmamaktadır.
U
U

UCB


Haberler

UCB drops to bottom of BEL 20 after KBC downgrade

BUZZ-UCB drops to bottom of BEL 20 after KBC downgrade ** Shares in UCB UCB.BR fall 2.7% to the bottom of Belgium's BEL 20 .BFX blue-chip index after KBC Securities downgrades the biotech firm to "hold" from "accumulate" ** KBC says the downgrade is primarily caused by the substantial increase in UCB's share price, which has risen 135% from its Nov
U

Crest Nicholson, JDE Peet's, L'Oreal

EUROPE RESEARCH ROUNDUP-Crest Nicholson, JDE Peet's, L'Oreal Aug 14 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Crest Nicholson Holdings, JDE Peet's and L'Oreal, on Wednesday. HIGHLIGHTS * A.P. Moller-Maersk MAERSKb.CO : Deutsche Bank cuts PT to DKK 9217 from DKK 9283 * British American Tobacco Plc BATS.L : Barclays raises target price to 3100p from 2650p * Crest Nicholson Holdings Plc CRST.L : Peel Hunt cuts to hold from add *
A
B
C
C
D
E
E
E
H
J
L
N
R
S
S
T
U
U
U
A
E
F
P

UCB Announces EU Comission Approval For 320 Mg Devices Of Bimzelx[®]

BRIEF-UCB Announces EU Comission Approval For 320 Mg Devices Of Bimzelx[®] Aug 5 (Reuters) - Ucb SA UCB.BR : ANNOUNCES EUROPEAN COMMISSION APPROVAL FOR 320 MG DEVICE PRESENTATIONS OF BIMZELX[®] PATIENTS REQUIRING A 320 MG DOSE OF BIMEKIZUMAB WILL NOW HAVE AN ALTERNATIVE SINGLE-INJECTION OPTION OF BOTH PRE-FILLED SYRINGE AND PRE-FILLED PEN Source
U

Arkema, Man Group, Shell

EUROPE RESEARCH ROUNDUP- Arkema, Man Group, Shell Aug 2 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Arkema, Man Group and Shell, on Friday. HIGHLIGHTS * Arkema SA AKE.PA : HSBC raises target price to EUR 105 from EUR 103 * Berkeley Group BKGH.L : Jefferies raises target price to 4,936p from 4,834p * Diageo Plc DGE.L : Morgan Stanley cuts target price to 2200p from 2380p * Man Group Plc EMG.L : Peel Hunt cuts to add from buy * Sh
A
A
A
A
A
B
B
B
B
B
C
C
C
D
E
E
M
R
S
S
U
A
B
T

Greencore, UCB, Unilever

EUROPE RESEARCH ROUNDUP-Greencore, UCB, Unilever July 26 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Greencore, UCB, and Unilever, on Friday. HIGHLIGHTS * Greencore GNC.L : HSBC raises target price to 190p from 160p * Lonza Group AG LONN.S : JP Morgan raises target price to CHF 645 from CHF 600 * Sartorius Stedim Biotech STDM.PA : HSBC cuts target price to EUR 310 from EUR 360 * UCB SA UCB.BR : TD Cowen raises target price to E
A
A
A
B
B
B
B
B
C
D
D
E
G
G
G
L
N
N
P
R
S
U
A
A
A
A
A
A
B
D
J

UCB rises on H1 results 'clear beat'

BUZZ-UCB rises on H1 results 'clear beat' ** Shares in UCB UCB.BR rise 1.7%, pares gains after rising as much as 3%, after the Belgian biopharmaceutical group posted a "clear beat" in half-year results, says KBC ** "UCB's product sales land well ahead of consensus now that it is gaining steam across its 5 growth drivers, and especially Bimzelx," -
U

UCB SA Confirms Financial Guidance For 2024

BRIEF-UCB SA Confirms Financial Guidance For 2024 July 25 (Reuters) - Ucb SA UCB.BR : FINANCIAL GUIDANCE FOR 2024 CONFIRMED OUR 2025 COMMITMENT FOR GROWING TOP LINE TO AT LEAST EUR 6 BILLION AND A SIGNIFICANT IMPROVED MARGIN STANDS- CFO REVENUE IN FIRST HALF OF 2024 REACHED EUR 2.79 BILLION H1 UNDERLYING PROFITABILITY (ADJUSTED. EBITDA2) WAS EUR 65
U

UCB Announces Approval Of Its Epilepsy Drug Briviact In Japan

BRIEF-UCB Announces Approval Of Its Epilepsy Drug Briviact In Japan June 26 (Reuters) - Ucb SA UCB.BR : UCB'S EPILEPSY DRUG BRIVIACT(BRIVARACETAM) APPROVED IN JAPAN FOR TREATMENT OF FOCAL ONSET SEIZURES BRIVARACETAM WILL OFFER INCREASED TREATMENT CHOICE TO PHYSICIANS AND PATIENTS IN JAPAN LIVING WITH EPILEPSY Source text for Workspace: nNDL4zkFFf F
U

Hochtief, Telenor, Zalando SE

EUROPE RESEARCH ROUNDUP-Hochtief, Telenor, Zalando SE June 24 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Hochtief AG, Telenor and Zalando SE, on Monday. HIGHLIGHTS * Associated British Foods ABF.L : HSBC raises target price to 3,075p from 3,010p * Berkeley Group Holdings Plc BKGH.L : Morgan Stanley cuts PT to 4,369p from 4,516p * Hochtief AG HOTG.DE : Jefferies raises target price to EUR 124 from EUR 109 * Telenor TEL.OL : HSB
A
A
A
A
B
B
C
D
D
E
E
E
E
H
H
I
I
K
L
M
M
O
S
T
T
U
V
Z
A
A
A
B
F
L
R
S
S

Hargreaves Lansdown, Segro, Umicore

EUROPE RESEARCH ROUNDUP-Hargreaves Lansdown, Segro, Umicore June 19 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Hargreaves Lansdown, Segro and Umicore, on Wednesday. HIGHLIGHTS * GEA Group AG G1AG.DE : Jefferies raises to buy from hold * Hargreaves Lansdown HRGV.L : Jefferies cuts to hold from buy * Oxford Instruments OXIG.L : Berenberg raises target price to 2,945p from 2,640p * Segro SGRO.L : Jefferies cuts to hold from buy *
A
A
B
B
B
B
B
B
B
D
D
G
G
G
G
G
H
H
I
K
K
L
M
R
S
S
S
U
U
V
A
S

Takeda's seizure drug fails to meet main goal in late-stage studies

UPDATE 2-Takeda's seizure drug fails to meet main goal in late-stage studies Adds details in paragraphs 6-10, Ovid shares in paragraph 13, background throughout June 17 (Reuters) - Japanese drugmaker Takeda 4502.T TAK.N said on Monday its experimental drug being tested for two epileptic disorders failed to reduce frequency of seizures in patients across late-stage studies.
U

Credit Agricole, Hermes, Whitbread

EUROPE RESEARCH ROUNDUP-Credit Agricole, Hermes, Whitbread June 12 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Credit Agricole, Hermes and Whitbread, on Wednesday. HIGHLIGHTS * Credit Agricole CAGR.PA : Jefferies raises to buy from hold * Flutter Entertainment Plc FLTRF.L : JP Morgan cuts target price to 20,700p from 21,300p * Hermes HRMS.PA : Barclays cuts target price to EUR 2320 from EUR 2410 * Renew Holdings Plc RNWH.L : Ber
A
A
A
A
B
B
C
G
H
H
H
H
H
I
M
R
R
R
S
S
U
W
A
F
S
S
Z

UCB Presents Two-Year Data From Phase 3 Studies, Open-Label Extension Evaluating Bimekizumab

BRIEF-UCB Presents Two-Year Data From Phase 3 Studies, Open-Label Extension Evaluating Bimekizumab June 12 (Reuters) - Ucb SA UCB.BR : FIRST PRESENTATION OF TWO-YEAR DATA FROM PHASE 3 STUDIES, AND OPEN-LABEL EXTENSION EVALUATING BIMEKIZUMAB PRESENTATIONS REGARD TREATMENT OF ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA) AND ACTIVE RADIO
U

UCB rises after JPM ups on Bimzelx prospects

BUZZ-UCB rises after JPM ups on Bimzelx prospects ** Shares in UCB UCB.BR rise around 3% after J.P.Morgan upgrades the Belgian biopharmaceutical group to "neutral" from "underweight" ** JPM cites "sustainable" trajectory for its psoriasis (PsO) treatment Bimzelx and prospects of its strong ramp next year in dermatological condition hidradenitis sup
J
U

Banco Bpm, Firstgroup, Xps Pensions

EUROPE RESEARCH ROUNDUP-Banco Bpm, Firstgroup, Xps Pensions June 11 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Banco Bpm, Firstgroup and Xps Pensions Group, on Tuesday. HIGHLIGHTS * Banco Bpm BAMI.MI : Morgan Stanley cuts to equal weight from overweight * Firstgroup Plc FGP.L : RBC raises target price to 200p from 195p * JCDecaux SE JCDX.PA : Deutsche Bank cuts to hold from buy * Next Plc NXT.L : HSBC raises target price to 9,
B
B
C
C
D
E
E
E
E
F
H
H
H
I
K
M
N
N
S
S
U
U
H
A
B
I

UCB: Positive CHMP Opinion For Two 320 Mg Device Presentations Of Bimzelx

BRIEF-UCB: Positive CHMP Opinion For Two 320 Mg Device Presentations Of Bimzelx May 31 (Reuters) - Ucb SA UCB.BR : UCB ANNOUNCES POSITIVE CHMP OPINION FOR TWO 320 MG DEVICE PRESENTATIONS OF BIMZELX(BIMEKIZUMAB) Further company coverage: UCB.BR (Gdansk Newsroom)
U

UCB Announces Publication Of Phase 3 Bimekizumab Trials

BRIEF-UCB Announces Publication Of Phase 3 Bimekizumab Trials May 23 (Reuters) - Ucb SA UCB.BR : ANNOUNCES PUBLICATION IN LANCET OF PHASE 3 BIMEKIZUMAB TRIALS IN MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA LANCET HAS PUBLISHED RESULTS FROM PHASE 3 BE HEARD I AND BE HEARD II TRIALS BIMEKIZUMAB CONSISTENTLY DEMONSTRATED SUSTAINED IMPROVEMENTS IN CLIN
U

FLSmidth, Neste, Sonova Holding

EUROPE RESEARCH ROUNDUP- FLSmidth, Neste, Sonova Holding May 20 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including FLSmidth, Neste and Sonova Holding, on Monday. HIGHLIGHTS * FLSmidth FLS.CO : JP Morgan raises target price to DKK 400 from DKK 310 * IMCD NV IMCD.AS : JP Morgan cuts target price to EUR 185 from EUR 188 * Neste Oyj NESTE.HE : Stifel cuts target price to EUR 37 from EUR 40 * Sonova Holding AG SOON.S : Morgan Stanley cuts
B
C
C
E
E
E
F
F
G
N
P
R
S
S
S
S
T
U
U
V
A
F
R



Şartlar

Popüler varlıklar

Bildirim: XM Group şirketlerinin her biri yalnızca gerçekleştirme hizmeti ve online yatırım platformumuza erişim sağlar. Herhangi bir kişinin web sitesinde bulunan veya web sitesi üzerinden sağlanan içeriği görüntülemesine ve/veya kullanmasına izin vermek, bu hizmeti değiştirmek veya genişletmek amaçlı değildir ve bu hizmeti ne değiştirir ne de genişletir. Bu tür erişim ve kullanım her zaman şunlara tabidir: (i) Şartlar ve Koşullar; (ii) Risk Uyarıları ve (iii) Tam Bildirim. Bu nedenle bu tür içerikler yalnızca genel bilgi amacıyla sağlanır. Özellikle, online yatırım platformumuzun içeriklerinin finans piyasalarında herhangi bir işleme girmek için bir teşvik veya bir teklif olmadığını lütfen dikkate alın. Herhangi bir finans piyasasında yatırım yapmak sermayeniz için önemli düzeyde risk taşır.

Online yatırım platformumuzda yayınlanan tüm materyaller yalnızca eğitim/bilgilendirme amaçlıdır ve finansal tavsiye, yatırım vergisi veya yatırım tavsiyesi ve önerileri ya da yatırım fiyatlarımızın kaydı veya herhangi bir finansal enstrümanda işlem yapılması için bir teklif veya teşvik ya da talep edilmemiş finansal promosyonları içermez ve içerdiği şeklinde bir değerlendirme yapılmamalıdır.

Görüşler, haberler, araştırma, analizler, fiyatlar, diğer bilgiler veya bu web sitesinde bulunan üçüncü taraf sitelere verilen bağlantılar gibi her türlü üçüncü taraf içeriğin yanı sıra XM tarafından hazırlanan içerik de “olduğu gibi” esasına göre, genel piyasa yorumu olarak sağlanır ve bir yatırım tavsiyesi oluşturmaz. Herhangi bir içeriğin yatırım araştırması olarak yorumlanmasıyla ilgili olarak, içeriğin bağımsız yatırım araştırmasını desteklemek üzere tasarlanmış yasal gerekliliklere uygun hazırlanmadığını ve bu amacın güdülmediğini, aynı şekilde ilgili yasalar ve mevzuatlar kapsamında pazarlama iletişimi olarak değerlendirileceğini dikkate almalı ve kabul etmelisiniz. Buradan erişebileceğiniz Bağımsız Olmayan Yatırım Araştırması Bildirimimizi ve yukarıdaki bilgilerle ilgili Risk Uyarımızı okuduğunuzdan ve anladığınızdan emin olun.

Risk uyarısı: Sermayeniz risk altında. Kaldıraçlı ürünler herkese uygun olmayabilir. Lütfen Risk Bildirimi'mizi dikkate alın.